1. Introduction {#sec1}
===============

Epidemiological evidence has revealed an inverse incidence between Alzheimer\'s disease (AD) and cancer that increases exponentially among aged cohorts \[[@B1], [@B2]\]. However, despite the clear differences in the etiology of the two diseases, including the premature death of neurons in AD and evasion of apoptosis in cancer, it has been suggested that common signaling pathways are involved in the two age-associated diseases \[[@B3]\]. Molecular comparative surveys of the two disease states have led to speculation of roles for p53 and the Wnt signaling pathway in both cancer and AD \[[@B4]\]. However, a global transcriptomic network comparison between the two diseases has yet to be completed \[[@B2]\].

Of interest, immune response is intimately related to both diseases \[[@B5]--[@B7]\]. In fact, based on an early colorectal cancer (CRC) transcriptome dataset \[[@B8]\], our previous study \[[@B9]\] found immunosuppression and immune cell infiltration even within normal-appearing cells in CRC patients. Similarly, in the brain, microglia and astrocytes involved in inflammation play a critical role in neurodegeneration \[[@B6], [@B7]\].

Despite continuous efforts to understand the individual molecular mechanisms of the two diseases, distinction of the global effects of immune response toward specific signal transduction usage in the two diseases has not been established. Here, we systematically inspected the two diseases representing phenotypically opposite cell fates, death and survival, by utilizing functional enrichment analysis and a systems biology approach \[[@B9]\]. This functional enrichment indicated that inflammatory response was significantly involved in both diseases. Subsequently, we found, by the systems biology approach, that various pathways within each disease network were comprised of common inflammation-associated genes.

2. Materials and Methods {#sec2}
========================

2.1. Functional Enrichment Comparison of CRC and AD {#sec2.1}
---------------------------------------------------

Throughout the paper, we compared one colorectal cancer (CRC) dataset (GEO accession GSE4107) \[[@B8]\] with two AD datasets (GEO accessions GSE1297, GSE12685) \[[@B10], [@B11]\] from GEO (see details in Supplementary Table S1 in Supplementary Material available online at <http://dx.doi.org/10.1155/2015/205247>). We used Ingenuity Pathway Analysis (IPA, Qiagen, Valencia, CA, USA) to inspect functionally enriched terms within the IPA "Diseases and Functions" ontology, revealing the top 5 significant terms for the three datasets ([Figure 1(a)](#fig1){ref-type="fig"}). For functional enrichment analysis, we uploaded the expression fold-changes of all the genes for the three datasets into IPA: in the CRC dataset, the expression fold-changes of patients versus controls were obtained and in AD, the fold-changes of AD patients versus controls were obtained.

Since cancer and AD are phenotypically opposite (cell survival versus cell death), we obtained oppositely expressed common genes between the two diseases. Based on all the genes\' fold-changes from the three datasets, we obtained the common genes as shown in [Figure 1(b)](#fig1){ref-type="fig"}.

2.2. Network Construction of CRC and AD {#sec2.2}
---------------------------------------

For generating networks from the three datasets, we applied our previous subpathway-based systems biology approach \[[@B9]\]. In brief, KEGG pathways were decomposed to all their possible paths (i.e., subpathways). In a given dataset, we applied a statistical test to each subpathway to determine whether the gene expression levels agreed with edge types (e.g., activation, inhibition) of the subpathway. Subsequently, in the dataset, we gathered the statistically significant subpathways (*P* values \<0.05) that comprised the network.

3. Results and Discussion {#sec3}
=========================

3.1. Overview {#sec3.1}
-------------

While cancer and AD are two of the most common diseases worldwide (15.6 million versus 7.7 million new cases per year) relating to aging, their phenotypes are opposite: cell death (neurons) in AD versus survival (mostly epithelial cells) in cancer. Also, AD patients are less susceptible to cancer and vice versa \[[@B1]\]. Consequently, we aimed at understanding changes at the molecular level between the two diseases. First, we inspected functional enrichment comparison of a cancer dataset (from our previous study) and the two AD datasets. Second, due to the involvement of inflammation in both pathologies \[[@B12], [@B13]\], we aimed to identify global network differences between the two diseases to possibly identify differential inflammation environments and differential chemokine/cytokine receptor usages. For this purpose, we selected colorectal cancer (CRC) as the cancer dataset to extend our previous result \[[@B9]\]. We also obtained the two independent AD datasets from GEO (Supplementary Table S1).

3.2. Functional Enrichment Comparison of CRC and AD: Inflammation-Related Genes {#sec3.2}
-------------------------------------------------------------------------------

We used Ingenuity Pathway Analysis (IPA) to perform functional pathway enrichment of early CRC and AD. IPA reported the top 5 functional categories from its "Diseases and Functions" ontology. In [Figure 1(a)](#fig1){ref-type="fig"}, inflammatory response-related genes, as well as cancer-associated genes, were significantly enriched in the CRC and the AD datasets.

[Figure 1(b)](#fig1){ref-type="fig"} shows common genes that were inversely expressed between the two phenotypically opposite diseases. Considering that the biopsy tissues for the datasets contain immune cells, inflammatory response is reasonable for functional enrichment.

Out of the common genes in [Figure 1(b)](#fig1){ref-type="fig"},*ARF6* was upregulated in the AD datasets but downregulated in the CRC dataset. ARF6, a small GTPase \[[@B14]--[@B16]\], regulates early endosome internalization of the protease BACE1, Beta-Site APP-Cleaving Enzyme 1. This internalization enables BACE1 to encounter and cleave intracellular amyloid precursor proteins (APPs), leading to amyloidogenic processing for the accumulation A*β* dimers in neurons, a hallmark of AD pathology \[[@B17]\].

*CCR6* (in [Figure 1(b)](#fig1){ref-type="fig"}) was upregulated in CRC but downregulated in both AD datasets. CCR6 is an important surface marker of immunosuppressive immune cells in the CRC tumor microenvironment \[[@B18]\]. Regulatory T cells (T~Reg~ cells) expressing CCR6 are recruited to a tumor mass by tumor-associated macrophages (TAMs), and tumor development is enhanced by CCR6 binding to its ligand CCL20 (CRC 1.721-fold of overcontrol in the GSE4107 dataset) secreted by tumor cells \[[@B18]\]. This scenario agrees with our previous result, indicating T~Reg~ cell infiltration into normal-appearing mucosa in CRC patients \[[@B9]\]. Considering that T and B cells do not exist in brain, the low expression of the T~Reg~ cell surface markers in AD patients is not surprising.

We further dissected the common genes (28 and 35 genes in white circles in the Venn diagram in [Figure 1(b)](#fig1){ref-type="fig"}) in terms of inflammation, considering that inflammatory response was the highest enrichment in all three datasets. For this purpose, we selected several terms involved in inflammation from the IPA "Diseases and Functions" ontology (see the terms and entries in Supplementary Table S2). Out of the genes common to the three datasets, 16 were oppositely expressed between the two diseases in terms of IPA inflammation-related terms ([Table 1](#tab1){ref-type="table"}).

3.3. Network Construction of CRC and AD {#sec3.3}
---------------------------------------

Next, we constructed molecular networks for the two diseases. By applying our previous systems biology method to the three disease datasets, we obtained CRC and AD pathogenesis networks (Supplementary Figures S1--S3). We summarized the most significant 100 subpathways for each network (Supplementary Tables S3--S5) in order to see the signaling in detail. These subpathways were assigned to various pathways in CRC and AD (Supplementary Tables S3--S5), suggesting that, in addition to inflammatory response inferred by our functional enrichment comparison, those pathways (not assigned to inflammation) remain largely unexplored in CRC or AD. Of interest, we found pathways previously unassociated with the two diseases, including Hedgehog signaling, axon guidance, ECM-receptor interaction, and WNT signaling ([Table 3](#tab3){ref-type="table"}). In CRC, WNT3 facilitates crosstalk between the Hedgehog and Wnt signaling pathways ([Table 3](#tab3){ref-type="table"}). Similarly, ECM-receptor interaction was oppositely regulated between the two diseases.

3.4. Opposite Signaling Pathway Expression between CRC and AD by Inflammation-Related Genes {#sec3.4}
-------------------------------------------------------------------------------------------

The AD datasets were prepared from frontal cortex synaptoneurosomes and hippocampi. Both brain regions include neurons, as well as astrocytes and microglia \[[@B19], [@B20]\]. In our previous analysis \[[@B9]\] of the CRC dataset, immune cells were infiltrating. Considering immune cell involvement in the two diseases and their two opposite phenotypes, different inflammation-related molecule usage in signaling is self-evident.

So, we inspected the 16 genes\' (in [Table 1](#tab1){ref-type="table"}) differential usage of the CRC and AD networks (from Supplementary Figures S1--S3). [Table 2](#tab2){ref-type="table"} indicates that 16 genes were involved in extensive signaling transduction in both the CRC and AD networks, and all were inversely expressed between the two diseases.

Out of the 16 gene products, CD36 (a class B scavenger receptor) was found in microglia and vascular endothelial cells of AD patient brains \[[@B21]\]. Activation of CD36 and PPAR delta (gene symbol: PPARD, upregulated in both AD datasets in [Table 2](#tab2){ref-type="table"}) resulted in FoxO1 activation in a functional study of muscle cells \[[@B22]\]. Considering that microglia are activated by FoxO1 \[[@B23]\], the two genes (*CD36* and*PPARD*) could be involved in inflammation of AD patient brains.

Another intriguing observation was the opposite expression of a cell growth (antiapoptosis) gene,*MAPK*, which was upregulated in CRC and downregulated in AD, while two apoptosis pathways genes,*FAS* (part of the extrinsic apoptosis pathway) and*BAD*, showed the opposite pattern (up in AD and down in CRC) ([Table 2](#tab2){ref-type="table"}). This apoptosis versus cell survival relationship has been previously postulated to explain the inverse risk correlation between malignant and neurodegenerative diseases.

4. Conclusions {#sec4}
==============

In general, single gene expression analysis looks into highly differentially expressed genes under a certain cutoff (e.g., *P* value, fold-change). However, in real biological problems, signaling proteins involved in phenotype differences may not show a drastic expression-level change \[[@B9], [@B24]\]. Also, considering that phenotype change or disease results from dysregulation of complex relationships between biological components \[[@B25], [@B26]\], a strict cutoff usage in single gene analysis can miss signal flow. For example, some biological entities belonging to the flow would be filtered out under a certain cutoff. Along that line, we applied our previous systems biology method \[[@B9]\] for describing the interdependency underlined in the diseases. In summary, we found that inflammatory response was a very important mechanism in two diseases of opposite phenotypes, that is, cancer (cell survival) and Alzheimer\'s disease (cell death). The inflammation-related common genes between the diseases regulated opposite gene expression in various cell signaling in the two-disease networks. In other words, the inflammation-related genes in [Table 2](#tab2){ref-type="table"} utilized different pathways according to the disease states, leading to different signaling transductions. Further investigation of such networks could provide knowledge into the immunological bases for the progression of both of these devastating diseases.
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![IPA functional enrichment of the CRC and the AD datasets. (a) Top 5 functional categories from "Diseases and Functions" ontology for the datasets are represented. The *y*-axis represents the minus logarithms of the *P* values. The higher the value on the *y*-axis is, the more statistically significant it becomes. The *x*-axis represents the functional categories. (b) The common genes inversely expressed between the two diseases are indicated by white ovals (see details in [Section 2](#sec2){ref-type="sec"}). In the Venn diagrams, "GSE12685 (AD) Dn" is the downregulated gene set in AD patients versus controls. "GSE12685 (AD) Up" is the upregulated gene set in AD patients versus controls. The notation is similar to the GSE1297 (AD) dataset and the GSE4107 (CRC) dataset.](BMRI2015-205247.001){#fig1}

###### 

Inflammation-associated genes common to both AD and CRC show opposite expression patterns. The 16 oppositely expressed common genes (in [Figure 1(b)](#fig1){ref-type="fig"}) between AD and CRC were assigned to inflammation-associated functional terms in IPA.

  Functional category              Downregulated in AD and upregulated in CRC                                 Upregulated in AD and downregulated in CRC
  -------------------------------- -------------------------------------------------------------------------- --------------------------------------------
  Chemokine                        PTPN6^+∗\#^, IRAK3^+∗\#^, FLT3^+∗\#^                                       BAD^+∗\#^, CD36^+∗\#^
                                                                                                              
  Inflammation relating to CRC     DDIT3^+∗\#^, FAS^+∗\#^, IRF3^+∗\#^                                          
                                                                                                              
  Inflammation relating to brain   CCR6^+∗\#^, CD28^+∗\#^, DDIT3^+∗\#^, FAS^+∗\#^, FCER1G^+∗\#^, NGFR^+∗\#^   PPARD^+∗\#^
                                                                                                              
  Cytokines relating to cancer     CD28^+∗\#^, FN1^+∗\#^                                                      ABL1^+∗\#^, EGFR^+∗\#^
                                                                                                              
  Cytokines relating to brain                                                                                 CD36^+∗\#^

^+^Genes detected in the CRC network from GSE4107 dataset.

^\*^Genes detected in the AD network from GSE1297 dataset.

^\#^Genes detected in the AD network from GSE12685 dataset.

###### 

KEGG pathways associated with the 16 oppositely expressed common genes (in [Table 1](#tab1){ref-type="table"}) in the AD and the CRC networks. From the AD and the CRC networks, pathway information of the 16 genes was obtained. The 16 genes were inversely expressed in the pathways between the AD and the CRC networks.

  Gene symbols   Pathways                                                                                                   CRC (GSE4107)   AD (GSE12685)   AD (GSE1297)
  -------------- ---------------------------------------------------------------------------------------------------------- --------------- --------------- --------------
  PTPN6          hsa04662_B\_cell_receptor_signaling_pathway; hsa04630_Jak-STAT_signaling_pathway; hsa05140_Leishmaniasis   Up              Down            Down
  IRAK3          hsa04722_Neurotrophin_signaling_pathway                                                                                                    
  FLT3           hsa05221_Acute_myeloid_leukemia                                                                                                            
  DDIT3          hsa04010_MAPK_signaling_pathway                                                                                                            
  FAS            hsa04115_p53_signaling_pathway; hsa04650_Natural_killer_cell_mediated_cytotoxicity                                                         
  IRF3           hsa04622_RIG-I-like_receptor_signaling_pathway; hsa04623_Cytosolic_DNA-sensing_pathway                                                     
  CCR6           hsa04060_Cytokine-cytokine_receptor_interaction; hsa04062_Chemokine_signaling_pathway                                                      
  CD28           hsa04660_T\_cell_receptor_signaling_pathway; hsa05416_Viral_myocarditis                                                                    
  FCER1G         hsa04650_Natural_killer_cell_mediated_cytotoxicity                                                                                         
  NGFR           hsa04722_Neurotrophin_signaling_pathway                                                                                                    
  FN1            hsa04512_ECM-receptor_interaction                                                                                                          
                                                                                                                                                            
  BAD            hsa04510_Focal_adhesion; hsa05223_Non-small_cell_lung_cancer; hsa05210_Colorectal_cancer                   Down            Up              Up
  CD36           hsa03320_PPAR_signaling_pathway; hsa04512_ECM-receptor_interaction                                                                         
  PPARD          hsa05221_Acute_myeloid_leukemia; hsa04310_Wnt_signaling_pathway                                                                            
  ABL1           hsa04012_ErbB_signaling_pathway; hsa04722_Neurotrophin_signaling_pathway                                                                   
  EGFR           hsa05214_Glioma; hsa04012_ErbB_signaling_pathway                                                                                           

###### 

Subpathways previously not associated with the two diseases. These subpathways were selected from the most significant 100 subpathways in each network. Subpathway (linear signaling flow) with fold-change (the numeral in parenthesis) of the disease group over the control group is represented in each dataset. The most significant 100 subpathways for each dataset are provided in Supplementary Tables S3--S5. The notation in the flow is "B \<- A: A activates B" and "B ∣- A: A represses B."

  KEGG pathway                                                                                                                                         GSE4107 (CRC) subpathway; *P* value                                                                                                                                                  GSE1297 (AD) subpathway; *P* value                                           GSE12685 (AD) subpathway; *P* value
  ---------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------
  Hedgehog signaling (hsa04340)                                                                                                                        PTCH1 (1.863) \<- GLI2 (2.878) ∣- CSNK1G1 (0.587); 0.000035                                                                                                                                                                                                       PTCH2 (0.938) \<- GLI3 (0.682) ∣- GSK3B (1.513); 0.0015
  WNT3 (3.147) \<- GLI2 (2.878) ∣- CSNK1G1 (0.587); 0.000223                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                         
  Axon guidance (hsa04360)                                                                                                                                                                                                                                                                                                                  PAK3 (0.732) \<- RAC1 (0.943) ∣- PLXNB3 (1.627) \<- SEMA4C (1.283); 0.0008   CFL1 (1.157) ∣- LIMK1 (0.896) \<- PAK4 (0.871) \<- RAC3 (0.892) \<- PLXNA3 (0.954) \<- FES (0.841); 0.0011
                                                                                                                                                                                                                                                                                                                                                                                                                         
  WNT signaling (hsa04310)                                                                                                                             JUN (4.179) \<- TCF7L1 (2.735) \<- CTNNB1 (2.562) ∣- GSK3B (0.735) ∣- DVL3 (1.608) \<- FZD10 (6.256) \<- WNT3 (3.147) \<- PORCN (1.279); 0.000114                                                                                                                  
  JUN (4.179) \<- TCF7L1 (2.735) \<- CTNNB1 (2.562) ∣- GSK3B (0.735) ∣- DVL3 (1.608) \<- APC2 (2.201) \<- AXIN2 (2.307) \<- CSNK1A1 (1.963); 0.00016                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                         
  Pathways in cancer (hsa05200)                                                                                                                        MMP2 (3.031) \<- JUN (4.179) \<- MAPK1 (2.425) \<- MAP2K1 (1.162) \<- ARAF (4.631) \<- HRAS (1.027) \<- SOS1 (1.624) \<- GRB2 (1.613) \<- IGF1R (2.299) \<- IGF1 (2.529); 0.000022                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                         
  ECM-receptor interaction (hsa04512)                                                                                                                  SDC2 (3.091) \<- TNC (9.557); 0.000026                                                                                                                                               SDC3 (0.849) \<- COL5A2 (0.162); 0.003                                       SDC1 (0.865) \<- COL3A1 (0.865); 0.0017
  SDC2 (3.091) \<- FN1 (5.594); 0.000125                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                         
  Neurotrophin signaling (hsa04722)                                                                                                                                                                                                                                                                                                                                                                                      BAD (1.279) ∣- AKT2 (0.856) \<- PDK1 (0.943) \<- PIK3CD (0.576) \<- GAB1 (0.997) \<- SHC2 (0.844) \<- NTRK1 (0.945) \<- NTF3 (0.784); 0.0008

[^1]: Academic Editor: Junwen Wang
